Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | MAP2K7 | O14733 | 3/20 | 0.51 |
| ▸ | KIT | P10721 | 10/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | AKT1 | P31749 | 4/20 | 0.45 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4086883 | 0.85 | MAP2K7 (0.52) | HPGDSMN1; SMN2GAAMAP2K7KIT | |
| SCHEMBL4086517 | 0.81 | MAP2K7 (0.57) | HPGDSMN1; SMN2GAAMAP2K7KDM4E | |
| SCHEMBL13938385 | 0.80 | KIT (0.53) | HPGDSMN1; SMN2GAAKITLMNA | |
| SCHEMBL4082603 | 0.80 | KRAS (0.44) | MAP2K7KITAKT1 | |
| SCHEMBL3126359 | 0.79 | PDGFRA (0.56) | MAP2K7KITKDM4EALDH1A1 | |
| SCHEMBL13938416 | 0.79 | PDGFRB (0.53) | MAP2K7KIT | |
| SCHEMBL13962111 | 0.79 | PDGFRB (0.53) | MAP2K7KIT | |
| SCHEMBL13938364 | 0.78 | KIT (0.49) | HPGDSMN1; SMN2GAAKIT | |
| SCHEMBL14196561 | 0.78 | PDGFRB (0.55) | MAP2K7KITAKT1 | |
| SCHEMBL13938538 | 0.77 | LMNA (0.58) | HPGDSMN1; SMN2GAAMAP2K7KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090029982-A1 | PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| US-20080207632-A1 | PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207632-A1 | PROTEIN KINASE INHIBITORS | ERBB3, ERBB2, AXL | HPGD 4263/4885SMN1; SMN2 3097/4885GAA 2375/4885 |
| US-20090029982-A1 | PROTEIN KINASE INHIBITORS | CDK2, PACSIN2, AKT1 | HPGD 2141/4885SMN1; SMN2 3080/4885GAA 2353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.